- Trials with a EudraCT protocol (604)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
604 result(s) found for: Ovulation inhibition.
Displaying page 1 of 31.
EudraCT Number: 2017-004664-36 | Sponsor Protocol Number: EVE116-CT03-2017 | Start Date*: 2018-06-19 |
Sponsor Name:Evestra GmbH | ||
Full Title: Characterization of ovulation inhibition of a new vaginal delivery system containing trimegestone - an open-label, single-centre study in healthy females of childbearing potential | ||
Medical condition: Investigation of ovulation inhibition for indication of contraception | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-009177-10 | Sponsor Protocol Number: BAY86-5016/14348 | Start Date*: 2009-04-30 |
Sponsor Name:Bayer HealthCare AG | ||
Full Title: Multicenter, open-label, randomized study to evaluate inhibition of ovulation of two transdermal patch formulations containing 0.55 mg ethinylestradiol and either 1.05 or 2.1 mg gestodene in health... | ||
Medical condition: The trial will be performed in healthy female volunteers. The intended indication is femal contraception. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000115-32 | Sponsor Protocol Number: EVE112-CT02-2015 | Start Date*: 2016-02-25 | |||||||||||
Sponsor Name:Evestra GmbH | |||||||||||||
Full Title: Characterization of ovulation inhibition of a new vaginal delivery system (EVE 112, Evestra/Germany) containing etonogestrel and ethinylestradiol – an open label, single centre, comparative, parall... | |||||||||||||
Medical condition: Investigation of ovulation inhibition for indication of contraception. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001198-13 | Sponsor Protocol Number: 310805 | Start Date*: 2008-08-19 |
Sponsor Name:Bayer HealthCare AG/Bayer Schering Pharma AG | ||
Full Title: Multicenter, open-label, randomized, uncontrolled study to evaluate inhibition of ovulation of two transdermal patch formulations containing 0.55 mg ethinylestradiol and either 1.05 or 2.1 mg gesto... | ||
Medical condition: The trial will be performed in healthy female volunteers. The indended indication is female contraception. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-006633-41 | Sponsor Protocol Number: 310723 | Start Date*: 2007-04-11 | |||||||||||
Sponsor Name:Bayer Schering Pharma AG | |||||||||||||
Full Title: Monocenter, open-label, randomized study to determine the ovulation inhibitory effect of the combined oral contraceptives SH T04769G (0.015 mg Ethinylestradiol and 1.5 mg Dienogest in a modified re... | |||||||||||||
Medical condition: The aim of this monocenter, open-label, randomized study is to determine the ovulation inhibitory effect of the COC SH T04769G (0.15 mg Ethinylestradiol and 1.5 mg Dienogest in a modified release f... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001143-43 | Sponsor Protocol Number: EU-KKO-LNG-02-2018 | Start Date*: 2019-10-07 | ||||||||||||||||
Sponsor Name:Gedeon Richter Plc. | ||||||||||||||||||
Full Title: An Open-label, Multi-center, Pharmacokinetic/Pharmacodynamic Study to Evaluate the Effect of a Single Dose of Levonorgestrel 1.5 mg Tablet on Ovulation Inhibition during Mid-follicular Phase in Und... | ||||||||||||||||||
Medical condition: Ovulation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021195-28 | Sponsor Protocol Number: BAY 98-7161 / 14835 | Start Date*: 2011-02-25 |
Sponsor Name:Bayer HealthCare AG | ||
Full Title: Single-center, randomized, placebo-controlled, double-blind, parallel group study to evaluate whether a single-dose of either 20 mg piroxicam, 40 mg piroxicam or 80 mg piroxicam shows an effect on... | ||
Medical condition: Emergency Contraception | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-003830-26 | Sponsor Protocol Number: LPRI-421/201 | Start Date*: 2017-02-24 | |||||||||||
Sponsor Name:Exeltis France | |||||||||||||
Full Title: Single center, phase II, open label randomized clinical trial to evaluate the inhibition of ovulation of three prolonged release formulations containing a combination of Dienogest and Ethinyl Estra... | |||||||||||||
Medical condition: Women’s healthcare (contraception, inhibition of ovulation). | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000041-12 | Sponsor Protocol Number: 49/11/EDG/TP2 | Start Date*: 2012-03-23 | |||||||||||
Sponsor Name:Zentiva k.s. Prague | |||||||||||||
Full Title: Characterisation of ovulation inhibition and effects on metabolic parameters and haemostatic system of multiple administrations of a fixed-dose combination product containing 0.02 mg ethinylestradi... | |||||||||||||
Medical condition: Investigation of ovulation inhibition, effects on metabolic parameters and haemostatic system for indication of contraception | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000089-41 | Sponsor Protocol Number: FCH-LNG-BW-01 | Start Date*: 2020-05-26 | |||||||||||
Sponsor Name:Foundation Consumer Healthcare (FCH) | |||||||||||||
Full Title: Randomized, Open-Label, Multicenter Proof-of-Principle Study to Assess the Effect of Single Doses of 1.5 mg and 3.0 mg Levonorgestrel During the Mid-Follicular Phase on the Inhibition of Ovulation ... | |||||||||||||
Medical condition: Inhibition of Ovulation in Women Across Body Weight Categories During the Mid-Follicular Phase | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001513-33 | Sponsor Protocol Number: CF111/204 | Start Date*: 2013-06-04 | |||||||||||
Sponsor Name:Laboratorios León Farma S.A. | |||||||||||||
Full Title: Phase II trial to evaluate the maintenance of ovulation inhibition with LF111 (drospirenone 4.0 mg 24/4 regimen) after scheduled 24-hour delays in pill intake. | |||||||||||||
Medical condition: Evaluation of ovulation inhibition with scheduled 24h delay in pill intake in healty young females of child bearing potential. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021255-81 | Sponsor Protocol Number: BAY 86-5016/15264 | Start Date*: 2010-09-13 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: Multicenter, open-label, randomized study to evaluate inhibition of ovulation during treatment with three transdermal patch formulations containing 0.55 mg ethinylestradiol (EE) and 2.10 mg gestod... | |||||||||||||
Medical condition: Prevention of Pregnancy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002350-22 | Sponsor Protocol Number: LR-201 | Start Date*: 2020-01-14 | |||||||||||
Sponsor Name:Chemo Research S.L. | |||||||||||||
Full Title: Multi-center, phase 2, open-label, randomized clinical trial to evaluate the inhibition of ovulation of 3 dosing strengths of levonorgestrel (LNG) vaginal delivery system (VDS), releasing during 28... | |||||||||||||
Medical condition: Women´s healthcare (Contraception, inhibition of ovulation) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004544-73 | Sponsor Protocol Number: 311623 | Start Date*: 2008-01-23 |
Sponsor Name:Bayer Schering Pharma AG | ||
Full Title: A double-blind, randomized, uncontrolled study to evaluate inhibition of ovulation of two oral estradiol / drospirenone regimens in healthy young female volunteers over a period of 3 treatment cycles | ||
Medical condition: The trial will be performed in healthy female volunteers. The intended indication is female contraception. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-003219-26 | Sponsor Protocol Number: MR-130A-01-TD-2001 | Start Date*: 2023-01-10 | |||||||||||
Sponsor Name:Mylan Pharmaceuticals, Inc | |||||||||||||
Full Title: An open-label, phase II, dose-finding study of three dose strengths of MR-130A-01 contraceptive transdermal patch containing norelgestromin (NGMN) in healthy pre-menopausal women | |||||||||||||
Medical condition: Investigation of ovulation inhibition for indication of contraception in healthy subjects | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005476-14 | Sponsor Protocol Number: PR3081 | Start Date*: 2007-11-09 |
Sponsor Name:Pantarhei Bioscience BV | ||
Full Title: A feasibility study into the contraceptive effect of estetrol alone or combined with either progesterone or desogestel by daily oral administration to healthy female volunteers for 28 days | ||
Medical condition: Only healthy volunteers will participate in this clinical trial. Intended indication: contraception. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-004267-40 | Sponsor Protocol Number: MIT-Es0001-C202 | Start Date*: 2017-01-16 | |||||||||||
Sponsor Name:Estetra SPRL | |||||||||||||
Full Title: A SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, TWO-ARM STUDY TO EVALUATE THE OVARIAN FUNCTION INHIBITION OF A MONOPHASIC COMBINED ORAL CONTRACEPTIVE (COC) CONTAINING 15 MG ESTETROL (E4) AND 3 MG DROSPIRE... | |||||||||||||
Medical condition: Hormonal contraception in woman seeking contraception | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-006044-14 | Sponsor Protocol Number: EB05-04-2020 | Start Date*: 2021-10-25 | ||||||||||||||||
Sponsor Name:Edesa Biotech Research Inc. | ||||||||||||||||||
Full Title: A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of EB05 + SOC vs. placebo + SOC in adult hospitalized patients with COVID19 | ||||||||||||||||||
Medical condition: SARS-CoV-2 Positive Pneumonia - level 3-7 in the nine-point COVID-19 severity scale: | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: PL (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002700-14 | Sponsor Protocol Number: NA-0113-200-EU | Start Date*: 2018-12-14 | |||||||||||
Sponsor Name:Navad Life Sciences Pte Ltd | |||||||||||||
Full Title: Single-center, open-label, adaptive design study to evaluate the influence on hormonal and ovarian function and vaginal bleeding pattern of different dosages of levonorgestrel administered once dai... | |||||||||||||
Medical condition: Investigation of ovulation inhibition for indication of contraception | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003921-27 | Sponsor Protocol Number: DORAGEN | Start Date*: 2019-06-25 |
Sponsor Name:Lluita contra la SIDA Foundation | ||
Full Title: Doravirine concentrations and antiviral activity in genital fluids in HIV-1 infected individuals. | ||
Medical condition: HIV infected individuals | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
